Abstract
Therapy for congenital ichthyoses remains unsatisfactory. Ichthyoses, characterized by barrier impairment with cutaneous erythema and scaling, share Th17 immune skewing, as in psoriasis, leading us to hypothesize that targeting IL-17A could reduce ichthyosis severity. Adults with ichthyosis were randomized 1:1 to receive 300 mg of secukinumab, an IL-17A inhibitor, or placebo every 4 wks in a 16-wk dual-center, double-blind trial, followed by 16-wk open-label and 20-wk extension phases for safety.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call